Skip to content

ImmunityBio, Inc. IBRX Net Investment in Lease

Net Investment in Lease at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
Biogen logo
BiogenBIIB
Moderna logo
ModernaMRNA
TG Therapeutics logo
TG TherapeuticsTGTX
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s net investment in lease?
ImmunityBio, Inc. (IBRX) reported net investment in lease of $33.03M in Q1 2026.
How has ImmunityBio, Inc.'s net investment in lease changed year-over-year?
ImmunityBio, Inc.'s net investment in lease increased by 3.9% year-over-year, from $31.78M to $33.03M.
What is the long-term trend for ImmunityBio, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s net investment in lease has grown at a 12.7% compound annual growth rate (CAGR), from $18.14M to $33.01M.